Primmune Therapeutics
Primmune Therapeutics is focused on harnessing innate immunity to treat cancer and viral infections. Founded by experts in drug design and immunology, the company develops selective TLR7 agonists, with its lead candidate PRTX007 designed to activate innate immune responses while avoiding pro-inflammatory side effects. The company's mission is to improve patient outcomes by activating plasmacytoid dendritic cells (pDCs) via the TLR7 pathway, supporting long-term disease control and treatment durability, especially in virally-mediated cancers and viral infections.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Clinical-stage oral TLR7 agonist prodrug (lead clinical candidate)
An orally administered, systemically active small-molecule TLR7 agonist prodrug designed to selectively activate plasmacytoid dendritic cells and induce Type I/III interferon responses without broad NF-κB–driven proinflammatory cytokine production; advanced through preclinical studies and a Phase I first-in-human trial.
Clinical-stage oral TLR7 agonist prodrug (lead clinical candidate)
An orally administered, systemically active small-molecule TLR7 agonist prodrug designed to selectively activate plasmacytoid dendritic cells and induce Type I/III interferon responses without broad NF-κB–driven proinflammatory cytokine production; advanced through preclinical studies and a Phase I first-in-human trial.
Services
Partner-based development and translational studies for innate-immune-targeting small molecules, including PK/PD and biomarker assessment.
Development of CMC plans, API development oversight, and global supply chain planning to support clinical-stage programs.
Partner-based development and translational studies for innate-immune-targeting small molecules, including PK/PD and biomarker assessment.
Development of CMC plans, API development oversight, and global supply chain planning to support clinical-stage programs.
Expertise Areas
- Innate immunology and TLR7-targeted therapeutics
- Small-molecule drug discovery and medicinal chemistry
- Translational sciences (PK/PD and immune biomarkers)
- Early-phase clinical development (Phase I)
Key Technologies
- Structure-based drug design
- Oral prodrug development
- TLR7 agonism for pDC activation
- PK/PD biomarker assays (IFN and immune cell activation)
News & Updates
Presentation at the Sting and TLR-Targeting Therapeutics Summit, May 25-27, 2021.
Presentation at the World Vaccine and Immunotherapy Congress West Coast & World Antiviral Congress, Nov 30 – Dec 2, 2021.
Presentation at the STING & TLR-Targeting Therapies Summit, May 9-11, 2023.
Presentation at the AACR Annual Meeting, 2020.
Presented at the American Association for the Study of Liver Disease Annual Meeting, 2023.
Activation of Innate and Adaptive Immune Response with a Clinical Stage TLR7 Agonist Prodrug PRTX007
Presented at the AACR Annual Meeting, 2023.
Presentation at the Sting and TLR-Targeting Therapeutics Summit, May 25-27, 2021.
Presentation at the World Vaccine and Immunotherapy Congress West Coast & World Antiviral Congress, Nov 30 – Dec 2, 2021.
Presentation at the STING & TLR-Targeting Therapies Summit, May 9-11, 2023.
Presentation at the AACR Annual Meeting, 2020.
Presented at the American Association for the Study of Liver Disease Annual Meeting, 2023.
Activation of Innate and Adaptive Immune Response with a Clinical Stage TLR7 Agonist Prodrug PRTX007
Presented at the AACR Annual Meeting, 2023.